Difference between revisions of "Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5 (Q9904)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 25, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: Page(s) (P105): 929-935, #quickstatements; #temporary_batch_1590074839150) |
||
| (One intermediate revision by the same user not shown) | |||
| Property / title | |||
| + | Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English) | ||
| Property / title: Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 929-935 | ||
| Property / Page(s): 929-935 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Sullivan RJ
0 references
2019
0 references
Nat. Med.
0 references
25
0 references
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English)
0 references
929-935
0 references
